Title

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Study Participants

    204
Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.
Study Started
Jun 30
2002
Primary Completion
Nov 30
2003
Study Completion
Feb 29
2004
Results Posted
Feb 05
2014
Estimate
Last Update
Aug 25
2017

Drug Fampridine-SR

25mg bid (twice daily)

Drug Placebo

Placebo

fampridine-SR 50mg/day Active Comparator

Placebo Placebo Comparator

Criteria

Inclusion Criteria:

Incomplete traumatic Spinal Cord Injury (at least 18 months prior and stable for 6 months)
Moderate to severe lower-limb spasticity
Able to give informed consent and willing to comply with protocol

Exclusion Criteria:

Pregnancy
History of seizures
Existing or history of frequent Urinary Tract Infections
History of drug or alcohol abuse
Allergy to pyridine-containing substances
Received a botox injection 4 months prior to study
Received an investigational drug within 30 days
Previously treated with 4-aminopyridine (4-AP)
Not on stable medication dosing in 3 weeks prior to study
Abnormal ECG or laboratory value at screening

Summary

Fampridine-SR 50mg/Day

Placebo

All Events

Event Type Organ System Event Term Fampridine-SR 50mg/Day Placebo

Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity

The Ashworth evaluates the functioning of two lower extremity muscle groups, the hamstring and quadriceps muscles, while in the supine position. The test measures extension of the right and left hamstring muscle and flexion of the right and left quadriceps muscle using the following 5-point grading scale: 1=no increased tone; 2=slight increase in tone, giving a "catch" when the affected part is moved in flexion or extension; 3=more marked increase in tone, but affected part is easily flexed; 4=considerable increase in tone, passive movement is difficult; 5=affected part is rigid in flexion and extension. The Ashworth Score was determined by adding all individual scores for each muscle group and dividing by four. Higher Ashworth Scores indicated greater spasticity.

Fampridine-SR 50mg/Day

-0.28
units on a scale (Mean)
Standard Error: 0.046

Placebo

-0.16
units on a scale (Mean)
Standard Error: 0.047

Double-blind Change From Baseline in Mean Subject's Global Impression (SGI) Scores

The SGI is a 7-unit ordinal scale used by the subject to evaluate the effects of study medication on his/her quality of life during the preceding week, with higher scores denoting greater satisfaction. A positive change score in SGI signifies improved outcome. The questionnaire consisted of one question (How do you feel about the effects of the investigational drug over the past 7 days?). The answer was based on a numerical rating scale where 1=terrible; 2=unhappy; 3=mostly dissatisfied; 4=neutral/mixed; 5=mostly satisfied; 6=pleased; 7=delighted.

Fampridine-SR 50mg/Day

Placebo

0.1
units on a scale (Mean)
Standard Error: 0.08

Double-blind Change From Baseline in Mean Spasm Frequency/Severity Scores

The Spasm Frequency score is the average rating by the clinician of the left and right arm(s) and leg(s), each evaluated on a 4-point scale (from 0=no spasms to 4=spontaneous spasms occurring more than ten times per hour), with higher scores denoting a greater degree of muscle spasms. The Spasm Severity score is the average rating of the left and right arm(s) and leg(s), each evaluated on a three-point scale (mild, moderate, or severe) as rated by the clinician on the basis of patient self-report. On both, a negative change in score signifies improvement in muscle spasms. The average Spasm Frequency/Spasm Severity Score was calculated as the average of the left and right non-missing scores.

Fampridine-SR 50mg/Day

Arm Spasm Frequency

-0.13
units on a scale (Mean)
Standard Error: 0.051

Arm Spasm Severity

-0.09
units on a scale (Mean)
Standard Error: 0.034

Leg Spasm Frequency

-0.12
units on a scale (Mean)
Standard Error: 0.051

Leg Spasm Severity

-0.14
units on a scale (Mean)
Standard Error: 0.040

Placebo

Arm Spasm Frequency

0.02
units on a scale (Mean)
Standard Error: 0.053

Arm Spasm Severity

-0.02
units on a scale (Mean)
Standard Error: 0.035

Leg Spasm Frequency

-0.1
units on a scale (Mean)
Standard Error: 0.052

Leg Spasm Severity

-0.07
units on a scale (Mean)
Standard Error: 0.041

Double-blind Change From Baseline in Mean Clinician's Global Impression (CGI) Scores

The supervising clinician rated the patient's neurological condition following treatment as compared to the screening visit on a seven-point scale (from 1=very much improved to 7=very much worse). The assessment was based on the clinician's overall impression of the patient's neurological status (specifically bowel, bladder, and sexual function; spasticity; and other neurological functions) and general state of health related to his or her participation in the study. Negative change scores indicated a change for the better.

Fampridine-SR 50mg/Day

-0.2
units on a scale (Mean)
Standard Error: 0.06

Placebo

-0.2
units on a scale (Mean)
Standard Error: 0.06

Stable-dose Change From Baseline in Mean American Spinal Injury Association(ASIA) Total Motor Score

Ten key muscle groups for the right and left sides were rated on a 0 (absent) to 5 (normal) scale, with a possible total score of 100. Higher positive change scores indicate improved motor function.

Fampridine-SR 50mg/Day

0.4
units on a scale (Mean)
Standard Error: 0.51

Placebo

0.7
units on a scale (Mean)
Standard Error: 0.49

Change From Baseline in Mean International Index of Erectile Function (IIEF) Score

Male patients were asked to complete the IIEF questionnaire on sexual function. The IIEF is a brief, reliable, and valid self-administered questionnaire of 15 questions (items) that were categorized into five domains: Erectile Function (EF) scores: 0-6 Severe dysfunction, 7-12 Moderate dysfunction, 13-18 Mild to moderate dysfunction, 19-24 Mild dysfunction, 25-30 No dysfunction. Orgasmic Function (OF) score range: 0-2 Severe dysfunction to 9-10 No dysfunction, Sexual Desire (SD) score range: 0-2 Severe dysfunction to 9-10 No dysfunction, Intercourse Satisfaction (IS) score range: 0-3 Severe dysfunction to 13-15 No dysfunction, and Overall Satisfaction (OS) score range: 0-2 Severe dysfunction to 9-10 No dysfunction. Domain scores were derived by summing the individual items within a given domain. Final scale ranges from 0 (negative) to 5 (positive). A positive change in IIEF domain scores signifies improvement.

Fampridine-SR 50mg/Day

EF (Fampridine-SR Number (N) =65, Placebo N=77)

0.8
units on a scale (Mean)
Standard Error: 1.09

IS (Fampridine-SR N=64, N=76)

0.4
units on a scale (Mean)
Standard Error: 0.55

OF (Fampridine-SR N=64, Placebo N=76)

0.3
units on a scale (Mean)
Standard Error: 0.36

OS (Fampridine-SR N=51, Placebo N=66)

0.4
units on a scale (Mean)
Standard Error: 0.27

SD (Fampridine-SR N=64, Placebo N=75)

Placebo

EF (Fampridine-SR Number (N) =65, Placebo N=77)

1.6
units on a scale (Mean)
Standard Error: 1.01

IS (Fampridine-SR N=64, N=76)

0.4
units on a scale (Mean)
Standard Error: 0.50

OF (Fampridine-SR N=64, Placebo N=76)

OS (Fampridine-SR N=51, Placebo N=66)

0.3
units on a scale (Mean)
Standard Error: 0.24

SD (Fampridine-SR N=64, Placebo N=75)

Change From Baseline in Mean Female Sexual Function Index (FSFI) Scores

The FSFI is a brief, reliable, and valid self-administered questionnaire of 19 questions (items). It contains six domains: Desire (2 items score range: 1 Very low or none at all to 5 Very high), Arousal (4 items score range: 0 No sexual activity to 5 Almost always or always), Lubrication (4 items score range: 0 No sexual activity to 5 Almost always or always), Orgasm (3 items score range: 0 No sexual activity to 5 Almost always or always), Satisfaction (3 items score range: 0 No sexual activity to 5 Very satisfied) and Pain (3 items score range: 0 Did not attempt intercourse to 5 Almost never or never). A positive change signifies improvement.

Fampridine-SR 50mg/Day

Arousal

0.6
units on a scale (Mean)
Standard Error: 0.37

Desire

0.7
units on a scale (Mean)
Standard Error: 0.26

Lubrication

0.7
units on a scale (Mean)
Standard Error: 0.45

Orgasm

0.2
units on a scale (Mean)
Standard Error: 0.18

Pain

0.7
units on a scale (Mean)
Standard Error: 0.47

Satisfaction (Fampridine-SR N=13, Placebo N=12)

0.4
units on a scale (Mean)
Standard Error: 0.25

Placebo

Arousal

0.2
units on a scale (Mean)
Standard Error: 0.40

Desire

0.2
units on a scale (Mean)
Standard Error: 0.28

Lubrication

-0.2
units on a scale (Mean)
Standard Error: 0.48

Orgasm

0.4
units on a scale (Mean)
Standard Error: 0.19

Pain

-0.1
units on a scale (Mean)
Standard Error: 0.50

Satisfaction (Fampridine-SR N=13, Placebo N=12)

0.3
units on a scale (Mean)
Standard Error: 0.26

Adjusted Mean Change in Subject Bladder/Bowel Function Diary Scores

Bowel/bladder questions pertaining to the average number of times per day the patient experienced accidental urination/leakage and the average number of bowel movements per day were asked of all patients daily. A negative change in patient bladder/bowel function diary score signifies improvement.

Fampridine-SR 50mg/Day

Number of Accidental Urination or Leakage

-0.2
episodes (Mean)
Standard Error: 0.20

Number of Bowel Movements

0.1
episodes (Mean)
Standard Error: 0.03

Placebo

Number of Accidental Urination or Leakage

-0.2
episodes (Mean)
Standard Error: 0.21

Number of Bowel Movements

Adjusted Mean Change in Subject Bowel Function Diary Scores

Bowel questions pertaining to the average number of minutes per day spent on bowel routine were asked of all patients daily. A negative change in patient bowel function diary score signifies improvement.

Fampridine-SR 50mg/Day

-0.7
minutes (Mean)
Standard Error: 0.90

Placebo

0.3
minutes (Mean)
Standard Error: 0.93

Total

203
Participants

Age, Continuous

40.9
Years (Mean)
Standard Deviation: 12.00

Race/Ethnicity, Customized

Sex: Female, Male

Overall Study

Fampridine-SR 50mg/Day

Placebo

Drop/Withdrawal Reasons

Fampridine-SR 50mg/Day

Placebo